Yiyun Huang Selected Research

McN 5652

1/2006	Lower serotonin transporter binding potential in the human brain during major depressive episodes.
12/2002	Occupancy of brain serotonin transporters during treatment with paroxetine in patients with social phobia: a positron emission tomography study with 11C McN 5652.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yiyun Huang Research Topics

Disease

18	Schizophrenia (Dementia Praecox) 01/2020 - 05/2002
14	Alcoholism (Alcohol Abuse) 01/2022 - 11/2005
13	Alzheimer Disease (Alzheimer's Disease) 01/2022 - 01/2010
9	Neoplasms (Cancer) 12/2021 - 07/2013
8	Cognitive Dysfunction 10/2022 - 01/2016
8	Substance-Related Disorders (Drug Abuse) 12/2019 - 01/2010
6	Wounds and Injuries (Trauma) 10/2021 - 09/2011
6	Mental Disorders (Mental Disorder) 08/2019 - 03/2005
5	Parkinson Disease (Parkinson's Disease) 01/2022 - 01/2014
5	Post-Traumatic Stress Disorders (Post Traumatic Stress Disorder) 10/2021 - 09/2011
4	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021 - 12/2013
4	Cocaine-Related Disorders (Cocaine Addiction) 01/2019 - 06/2004
4	Anxiety Disorders (Anxiety Disorder) 01/2017 - 12/2002
4	Major Depressive Disorder (Major Depressive Disorders) 11/2014 - 02/2004
3	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2022 - 01/2016
3	Epilepsy (Aura) 10/2020 - 12/2012
3	Ischemia 01/2019 - 12/2012
3	Brain Neoplasms (Brain Tumor) 03/2018 - 07/2013
3	Hypoxia (Hypoxemia) 01/2018 - 06/2015
2	Dementia (Dementias) 01/2022 - 01/2020
2	Pain (Aches) 01/2022 - 01/2016
2	Stroke (Strokes) 01/2022 - 01/2019
2	Spinal Cord Injuries (Spinal Cord Injury) 01/2022 - 11/2011
2	Obesity 01/2021 - 01/2020
2	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2020 - 10/2018
2	Central Nervous System Diseases (CNS Diseases) 01/2019 - 01/2018
2	Glioblastoma (Glioblastoma Multiforme) 03/2018 - 07/2013
2	Seizures (Absence Seizure) 02/2016 - 03/2005
2	Substance Withdrawal Syndrome (Withdrawal Symptoms) 05/2015 - 08/2014
2	Opioid-Related Disorders (Opiate Addiction) 05/2015 - 08/2014
2	Neuralgia (Stump Neuralgia) 01/2014 - 12/2012
2	Mood Disorders (Mood Disorder) 04/2013 - 12/2006
1	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 12/2022
1	Tobacco Use Disorder (Nicotine Dependence) 10/2022
1	Focal cortical dysplasia of Taylor 01/2022
1	Adenocarcinoma 12/2021
1	Triple Negative Breast Neoplasms 01/2021
1	Breast Neoplasms (Breast Cancer) 01/2021

Drug/Important Bio-Agent (IBA)

16	Dopamine (Intropin)FDA LinkGeneric 10/2022 - 11/2005
9	Serotonin (5 Hydroxytryptamine)IBA 01/2022 - 12/2002
8	Glycoproteins (Glycoprotein)IBA 01/2022 - 10/2018
7	kappa Opioid Receptors (kappa Opioid Receptor)IBA 01/2022 - 03/2005
7	Serotonin Plasma Membrane Transport Proteins (Serotonin Transporter)IBA 01/2022 - 06/2005
7	Proteins (Proteins, Gene)FDA Link 01/2022 - 11/2011
7	Opioid Receptors (Opioid Receptor)IBA 01/2019 - 04/2013
6	Biomarkers (Surrogate Marker)IBA 10/2022 - 01/2016
6	Pharmaceutical PreparationsIBA 01/2018 - 05/2002
5	Glutamic Acid (Glutamate)FDA Link 01/2020 - 12/2012
4	Opioid Analgesics (Opioids)IBA 01/2022 - 08/2014
4	ErbB Receptors (EGF Receptor)IBA 01/2021 - 12/2013
4	Cocaine (Cocaine HCl)IBA 01/2021 - 06/2004
4	Amphetamine (Amfetamine)FDA LinkGeneric 04/2015 - 11/2005
3	Naltrexone (ReVia)FDA LinkGeneric 01/2022 - 12/2019
3	Hydrocortisone (Cortisol)FDA LinkGeneric 10/2021 - 11/2014
3	EnzymesIBA 10/2021 - 01/2016
3	Phosphotransferases (Kinase)IBA 01/2021 - 12/2013
3	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2021 - 12/2013
3	Amyloid (Amyloid Fibrils)IBA 01/2021 - 01/2018
3	CannabinoidsIBA 12/2020 - 12/2012
3	Antipsychotic Agents (Antipsychotics)IBA 01/2020 - 03/2010
3	fluoromisonidazoleIBA 01/2018 - 06/2015
3	5-HT1A Serotonin ReceptorIBA 06/2011 - 12/2006
2	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 12/2022 - 01/2022
2	Tyrosine Kinase InhibitorsIBA 01/2021 - 04/2017
2	naxagolideIBA 01/2021 - 01/2020
2	5-HT2A Serotonin Receptor (5 HT2A Receptor)IBA 01/2020 - 02/2004
2	Dopamine D3 ReceptorsIBA 10/2016 - 01/2016
2	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)IBA 03/2016 - 01/2014
2	Neuroprotective AgentsIBA 03/2016 - 01/2014
2	Glycine Plasma Membrane Transport ProteinsIBA 03/2016 - 12/2015
2	Anticonvulsants (Antiepileptic Drugs)IBA 02/2016 - 01/2016
2	Cannabinoid Receptors (Cannabinoid Receptor)IBA 01/2016 - 10/2014
2	Dopamine Plasma Membrane Transport Proteins (Dopamine Transporter)IBA 09/2015 - 01/2014
2	Therapeutic UsesIBA 05/2015 - 08/2014
2	TabletsIBA 05/2015 - 01/2014
2	Morphine (MS Contin)FDA LinkGeneric 05/2015 - 08/2014
2	CB1 Cannabinoid Receptor (CB1 Receptor)IBA 10/2014 - 12/2012
2	Metabotropic Glutamate 5 ReceptorIBA 01/2014 - 08/2013
2	3- (6- methylpyridin- 2- ylethynyl)cyclohex- 2- enone- O- methyloximeIBA 01/2014 - 08/2013
2	N- (2- (4- (2- methoxyphenyl)- 1- piperazinyl)ethyl)- N- (2- pyridinyl)cyclohexanecarboxamideIBA 06/2011 - 12/2006
2	McN 5652IBA 01/2006 - 12/2002
1	Nicotine FDA Link 10/2022
1	7- (6- fluoropyridin- 3- yl)- 5H- pyrido(4,3- b)indoleIBA 01/2022
1	2- cyclohexylidenhydrazo- 4- phenyl- thiazoleIBA 01/2022
1	AD 5IBA 01/2022
1	2- (2- (dimethylaminomethylphenylthio))- 5- fluoromethylphenylamineIBA 01/2022
1	Biological ProductsIBA 01/2022
1	gallium 68 PSMA-11IBA 12/2021
1	gallium Ga 68 dotatateIBA 12/2021
1	Oxidoreductases (Dehydrogenase)IBA 10/2021
1	GlucocorticoidsIBA 10/2021
1	AS2471907IBA 10/2021
1	Proto-Oncogene Proteins c-metIBA 01/2021
1	amivantamab-vmjwIBA 01/2021
1	C-Reactive ProteinIBA 12/2020

Therapy/Procedure

6	Drug Therapy (Chemotherapy) 01/2019 - 07/2013
5	Therapeutics 01/2021 - 07/2013
3	Chinese Traditional Medicine (Traditional Chinese Medicine) 05/2015 - 01/2014
1	Castration 12/2021
1	Precision Medicine 01/2021